116 related articles for article (PubMed ID: 6202339)
1. [Inhibition of platelet aggregation and cyclic nucleotide phosphodiesterase (specifically cyclAMP) by 3-hydroxypyridine derivatives].
Kagan VE; Polianskiĭ NB; Muranov KO; Shvedova AA; Smirnov LD
Biull Eksp Biol Med; 1984 Apr; 97(4):416-8. PubMed ID: 6202339
[TBL] [Abstract][Full Text] [Related]
2. [Changes in the cyclic nucleotide level and the inhibition of human thrombocyte aggregation in 3-hydroxypyridine exposure].
Muranov KO; Polianskiĭ NB; Shvedova AA; Kagan VE; Smirnov LD
Biull Eksp Biol Med; 1986 Oct; 102(10):432-4. PubMed ID: 3768508
[TBL] [Abstract][Full Text] [Related]
3. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase.
Dell'Agli M; Maschi O; Galli GV; Fagnani R; Dal Cero E; Caruso D; Bosisio E
Br J Nutr; 2008 May; 99(5):945-51. PubMed ID: 17927845
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Nemoz G; Prigent AF
Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
[No Abstract] [Full Text] [Related]
6. Tissue selective inhibition of cyclic nucleotide phosphodiesterase by denbufylline.
Wilke R; Arch JR; Nicholson CD
Arzneimittelforschung; 1989 Jun; 39(6):665-7. PubMed ID: 2476135
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
8. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of cyclic nucleotide phosphodiesterase from the rod outer segments of the frog retina by 3-hydroxypyridine].
Polianskiĭ NB; Smirnov LD; Shvedova AA; Kagan VE
Nauchnye Doki Vyss Shkoly Biol Nauki; 1984; (1):27-31. PubMed ID: 6199045
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation.
Rickards KJ; Andrews MJ; Waterworth TH; Alexander GB; Cunningham FM
J Vet Pharmacol Ther; 2003 Aug; 26(4):277-82. PubMed ID: 12887610
[TBL] [Abstract][Full Text] [Related]
12. [Effect of antioxidants of the 3-hydroxypyridine class on cyclic 3', 5'-adenosine monophosphate phosphodiesterase activity].
Smirnov LD; Malykhina LS; Lazarevich VG; Fedorov NA
Biull Eksp Biol Med; 1983 Sep; 96(9):40-2. PubMed ID: 6311309
[TBL] [Abstract][Full Text] [Related]
13. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
14. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Gillespie E
Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
[No Abstract] [Full Text] [Related]
16. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
17. Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity.
Abbott BM; Thompson PE
Bioorg Med Chem Lett; 2006 Feb; 16(4):969-73. PubMed ID: 16290931
[TBL] [Abstract][Full Text] [Related]
18. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity.
Semmler J; Gebert U; Eisenhut T; Moeller J; Schönharting MM; Alléra A; Endres S
Immunology; 1993 Apr; 78(4):520-5. PubMed ID: 8388363
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
20. Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidil.
Mazurov AV; Menshikov MYu ; Leytin VL; Tkachuk VA; Repin VS
FEBS Lett; 1984 Jul; 172(2):167-71. PubMed ID: 6086387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
